论文部分内容阅读
非酒精性脂肪性肝病(non-alcoholic fatty liver disease,NAFLD)是常见的肝脏疾病,多认为是一种相对良性的疾病,约30%的NAFLD患者,肝脏脂肪变伴随着肝脏炎症,导致非酒精性脂肪性肝炎(NASH),而NASH则可能进一步发展致肝纤维化,进展至肝硬化,肝功能衰竭或肝癌[1]。因此对其诊断及治疗逐渐受到国内外学者的重视。然而,肝脂肪变和肝纤维化的诊断金标准是肝活检,而肝活检有创伤和风险,其
Non-alcoholic fatty liver disease (NAFLD) is a common liver disease that is considered as a relatively benign disease. In about 30% of NAFLD patients, hepatic steatosis accompanies liver inflammation and leads to non-alcoholic fatty liver disease Sexual Hepatitis B (NASH), NASH may further develop liver fibrosis, progression to cirrhosis, liver failure or liver cancer [1]. Therefore, its diagnosis and treatment are gradually receiving the attention of scholars at home and abroad. However, the gold standard for the diagnosis of hepatic steatosis and fibrosis is liver biopsy, while liver biopsy has trauma and risk of